UA112981C2 - Варіант людського gdnf - Google Patents

Варіант людського gdnf

Info

Publication number
UA112981C2
UA112981C2 UAA201311714A UAA201311714A UA112981C2 UA 112981 C2 UA112981 C2 UA 112981C2 UA A201311714 A UAA201311714 A UA A201311714A UA A201311714 A UAA201311714 A UA A201311714A UA 112981 C2 UA112981 C2 UA 112981C2
Authority
UA
Ukraine
Prior art keywords
gdnf
option
human
variant
human gdnf
Prior art date
Application number
UAA201311714A
Other languages
English (en)
Inventor
Донмайєнн Дон Мун Льюнг
Цзіжон Лу
Калпана Махеш Мерчант
Махмуд Ганем
Лінда Морін О'Брайан
Розамунд Керол Сміт
Original Assignee
Елі Ліллі Енд Компані
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Елі Ліллі Енд Компані filed Critical Елі Ліллі Енд Компані
Publication of UA112981C2 publication Critical patent/UA112981C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

Винахід стосується варіанта людського нейротрофного фактора з гліальних клітин (GDNF), фармацевтичної композиції, що його містить, та застосування варіанта людського GDNF як терапевтичного засобу. Винахід також стосується способу лікування хвороби Паркінсона за допомогою вказаного варіанта людського GDNF.
UAA201311714A 2011-04-11 2012-03-04 Варіант людського gdnf UA112981C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161474024P 2011-04-11 2011-04-11
PCT/US2012/031927 WO2012141936A1 (en) 2011-04-11 2012-04-03 Variants of human gdnf

Publications (1)

Publication Number Publication Date
UA112981C2 true UA112981C2 (uk) 2016-11-25

Family

ID=45932578

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201311714A UA112981C2 (uk) 2011-04-11 2012-03-04 Варіант людського gdnf

Country Status (28)

Country Link
US (1) US9243046B2 (uk)
EP (1) EP2696889B1 (uk)
JP (1) JP6093345B2 (uk)
KR (1) KR101554799B1 (uk)
CN (1) CN103635201B (uk)
AU (1) AU2012243178B2 (uk)
BR (1) BR112013026004B1 (uk)
CA (1) CA2833158C (uk)
CY (1) CY1119750T1 (uk)
DK (1) DK2696889T3 (uk)
EA (1) EA025129B1 (uk)
ES (1) ES2656020T3 (uk)
HR (1) HRP20171993T1 (uk)
HU (1) HUE036239T2 (uk)
IL (1) IL228102A (uk)
LT (1) LT2696889T (uk)
ME (1) ME02849B (uk)
MX (1) MX337206B (uk)
NO (1) NO2696889T3 (uk)
PL (1) PL2696889T3 (uk)
PT (1) PT2696889T (uk)
RS (1) RS56639B1 (uk)
SG (1) SG193483A1 (uk)
SI (1) SI2696889T1 (uk)
TW (1) TWI583698B (uk)
UA (1) UA112981C2 (uk)
WO (1) WO2012141936A1 (uk)
ZA (1) ZA201306556B (uk)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109996556A (zh) 2016-05-13 2019-07-09 分子医学研究院 治疗与ilc3细胞相关之疾病的方法
EP4076499A4 (en) * 2019-12-19 2023-11-01 Transfert Plus Societe en Commandite USE OF GLIAL CELL-DERIVED NEUROTROPHIC FACTOR (GDNF) FOR THE TREATMENT OF ENTERIC NEUROPATHIES
EP4347645A1 (en) 2021-06-03 2024-04-10 Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud Foundation Neuro-mesenchyme units control ilc2 and obesity via a brain-adipose circuit

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9205293A (es) 1991-09-20 1993-05-01 Syntex Sinergen Neuroscience J Factores neurotrofico derivado del glial
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
US6042579A (en) 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
DE19816186A1 (de) * 1998-04-14 1999-10-21 Univ Muenchen L Maximilians GDNF-kodierende DNA, Teile davon und GDNF-Varianten
US8946151B2 (en) 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
FI20070808A0 (fi) * 2007-10-25 2007-10-25 Mart Saarma GDNF:n silmukointivariantit ja niiden käytöt
CN101775072B (zh) * 2008-05-21 2012-09-05 王尚武 一种融合穿透肽的神经细胞营养因子gdnf
US8772236B2 (en) * 2009-02-06 2014-07-08 Pepscan Systems B.V. Truncated cystine-knot proteins

Also Published As

Publication number Publication date
NO2696889T3 (uk) 2018-04-14
HUE036239T2 (hu) 2018-06-28
AU2012243178B2 (en) 2016-09-29
SI2696889T1 (en) 2018-01-31
ZA201306556B (en) 2015-03-25
LT2696889T (lt) 2018-02-12
SG193483A1 (en) 2013-10-30
EA025129B1 (ru) 2016-11-30
CA2833158C (en) 2018-07-17
KR20130131470A (ko) 2013-12-03
EP2696889B1 (en) 2017-11-15
ME02849B (me) 2018-01-20
JP2014512369A (ja) 2014-05-22
PL2696889T3 (pl) 2018-04-30
BR112013026004B1 (pt) 2020-09-29
DK2696889T3 (en) 2018-01-22
IL228102A0 (en) 2013-09-30
CN103635201B (zh) 2016-11-09
ES2656020T3 (es) 2018-02-22
EP2696889A1 (en) 2014-02-19
CN103635201A (zh) 2014-03-12
US20130324474A1 (en) 2013-12-05
JP6093345B2 (ja) 2017-03-08
RS56639B1 (sr) 2018-03-30
AU2012243178A1 (en) 2013-09-05
TW201245220A (en) 2012-11-16
MX337206B (es) 2016-02-17
KR101554799B1 (ko) 2015-09-21
IL228102A (en) 2017-04-30
TWI583698B (zh) 2017-05-21
MX2013011919A (es) 2014-03-27
WO2012141936A1 (en) 2012-10-18
CA2833158A1 (en) 2012-10-18
BR112013026004A2 (pt) 2016-11-29
PT2696889T (pt) 2018-02-05
EA201370204A1 (ru) 2014-02-28
HRP20171993T1 (hr) 2018-02-09
CY1119750T1 (el) 2018-06-27
NZ614325A (en) 2015-07-31
US9243046B2 (en) 2016-01-26

Similar Documents

Publication Publication Date Title
IN2012DN06720A (uk)
PH12015500274B1 (en) Alkylpyrimidine derivatives for the treatment of viral infections and further diseases
WO2013151665A3 (en) Modified polynucleotides for the production of proteins associated with human disease
MY183637A (en) Compounds and uses thereof for the modulation of hemoglobin
EA201500535A1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и насыщения, снижения веса, композиция, фармацевтическая композиция, косметическая композиция и лекарственное средство
IN2014DN09434A (uk)
MX365525B (es) Compuestos que regulan la expresión de subunidades alfa de canales de sodio regulados por voltaje en enfermedades relacionadas con epilepsia mioclónica severa de la infancia.
MY188139A (en) Sodium channel modulators for the treatment of pain
EA201291336A1 (ru) Замещенные 5-фтор-1н-пиразолопиридины и их применение
CL2008000434A1 (es) Compuestos derivados de 2-amino-oxazolinas; proceso de obtencion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como depresion, ansiedad, estres, trastorno bipolar, entre otros.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
TN2012000414A1 (en) Forms of rifaximin and uses thereof
CL2012003604A1 (es) Compuestos heterociclicos derivados de piridina carboxamida sustituida; proceso de preparacion; composicion farmaceutica; combinacion farmaceutica; uso en el tratamiento de trastornos proliferativos celulares, enfermedad de parkinson, cancer, entre otros.
EA201300669A1 (ru) Замещенные 1-бензилциклоалкилкарбоновые кислоты и их применение
PH12015500713A1 (en) Acylaminopyrimidine derivatives for the treatment of viral infections and further diseases
EA201201658A1 (ru) Производные пиперидина и их применение для лечения метаболических нарушений
PH12015500746A1 (en) Benzamides
BR112014027087A2 (pt) tablete, método para fabricação de um tablete de mesilato de bromocriptina, método para fabricação de um tablete de mesilato de bromocriptina e método de tratamento para melhorar o controle glicêmico de diabetes do tipo 2 em um paciente
CL2014003325A1 (es) Compuestos derivados de difluoro-hexahidro-ciclopentaoxacinilos y difluoro-hexahidro-benzooxacinilos, inhibidores de bace 1; composicion farmaceutica; y su uso en el tratamiento de enfermedades con niveles elevados de beta-amiloide, tal como la enfermedad de alzheimer
CL2013002424A1 (es) Compuestos derivados de (piridin-4-il)-bencilamidas como moduladores alostericos de nachr alfa-7; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades como alzheimer, ansiedad, esquizofrenia, parkinson, entre otras.
CL2015000891A1 (es) Compuestos derivados de fenil-etinilo, moduladores de la actividad del receptor mglur5; proceso de preparacion; composicion farmaceutica; y uso en el tratamiento de la ansiedad, dolor, depresion,entre otras.
MX2014001393A (es) 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas.
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
UA112981C2 (uk) Варіант людського gdnf
EA201391742A1 (ru) Фармацевтическая композиция, включающая фексофенадин